Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. Rediti M, et al. Among authors: venet d. Nat Commun. 2024 Nov 29;15(1):10402. doi: 10.1038/s41467-024-54621-3. Nat Commun. 2024. PMID: 39613746 Free PMC article.
InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor.
Coletta A, Molter C, Duqué R, Steenhoff D, Taminau J, de Schaetzen V, Meganck S, Lazar C, Venet D, Detours V, Nowé A, Bersini H, Weiss Solís DY. Coletta A, et al. Among authors: venet d. Genome Biol. 2012 Nov 18;13(11):R104. doi: 10.1186/gb-2012-13-11-r104. Genome Biol. 2012. PMID: 23158523 Free PMC article.
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C. Sonnenblick A, et al. Among authors: venet d. BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2. BMC Med. 2015. PMID: 26234940 Free PMC article.
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. Fumagalli D, et al. Among authors: venet d. JAMA Oncol. 2017 Feb 1;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824. JAMA Oncol. 2017. PMID: 27684533 Free PMC article.
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. Hanker AB, et al. Among authors: venet d. Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Clin Cancer Res. 2017. PMID: 28381415 Free PMC article.
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.
Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Ignatiadis M, et al. Among authors: venet d. J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076. J Natl Cancer Inst. 2019. PMID: 29788230 Free PMC article. Clinical Trial.
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.
Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart M, Rothé F, Sotiriou C. Nguyen B, et al. Among authors: venet d. NPJ Breast Cancer. 2018 Aug 6;4:23. doi: 10.1038/s41523-018-0077-3. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30109263 Free PMC article.
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. Hanker AB, et al. Among authors: venet d. Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. Clin Cancer Res. 2019. PMID: 30770493 No abstract available.
54 results